Nascent Biotech, Inc. (NBIO)

Nascent Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-2.09	-2.09	-2.8	-0.47	-0.96	-4
Other Amortization	0.38	0.38	1.34	0.33	0.07	0.06
Stock-Based Compensation	0.88	0.88	0.76	0.12	0.79	1.1
Other Operating Activities	-0.52	-0.52	-0.77	-0.47	-0.78	0.47
Change in Accounts Receivable	-	-	-	0.75	-0.75	-
Change in Accounts Payable	0.26	0.26	-0.25	0.17	0.23	0.33
Change in Other Net Operating Assets	-0.1	-0.1	-0.07	-0.01	0.42	1.49
Operating Cash Flow	-1.19	-1.19	-1.79	0.41	-0.99	-0.55
Short-Term Debt Issued	0.23	0.23	1.93	0.2	0.35	0.2
Total Debt Issued	0.23	0.23	1.93	0.2	0.35	0.2
Short-Term Debt Repaid	-0.4	-0.4	-0.28	-0.52	-	-
Total Debt Repaid	-0.4	-0.4	-0.28	-0.52	-	-
Net Debt Issued (Repaid)	-0.18	-0.18	1.66	-0.32	0.35	0.2
Issuance of Common Stock	1.56	1.56	0.21	-	-	0.12
Financing Cash Flow	1.39	1.39	1.87	-0.32	0.99	0.43
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	-0
Net Cash Flow	0.2	0.2	0.08	0.09	-0	-0.13
Free Cash Flow	-1.19	-1.19	-1.79	0.41	-0.99	-0.55
Free Cash Flow Margin	-	-	-	41.35%	-131.57%	-
Free Cash Flow Per Share	-0.01	-0.01	-0.02	0.00	-0.01	-0.02
Cash Interest Paid	-	-	0.01	0.03	-	-
Levered Free Cash Flow	-0.95	-0.95	-0.01	0.4	-2.66	1.08
Unlevered Free Cash Flow	-1.08	-1.08	-0.28	0.28	-2.52	1.08
Change in Net Working Capital	0.57	0.57	-0.31	-0.45	2.43	-2.13

Source: S&P Capital IQ. Standard template.